Making the Case for Valeant Pharmaceuticals Intl Inc.: Why it’s Not Worth it Yet

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) stock has been in shambles in 2016, plummeting more than 83%, but there is reason to be optimistic about the stock’s potential in the long term.

| More on:
The Motley Fool

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) stock has been in shambles in 2016, plummeting more than 83%, but there is reason to be optimistic about the stock’s potential in the long term.

The pharmaceutical giant has experienced several setbacks over the last 11 months. Glaucoma drug latanoprostene bunod failed to garner approval from the Food and Drug Administration (FDA) over the summer due to problems at the facility it is manufactured. More recently, psoriasis drug brodalumab’s release was also pushed back.

Valeant’s glaucoma medication could make a major splash if its February 2017 launch comes to fruition, as there is a growing demand for glaucoma drugs that will rise steadily over the next seven years. Following a decline in the industry from 2012 to 2015, the glaucoma market has bounced back, and it was worth $5.7 billion in 2015. The market is expected to be worth $7.6 billion by 2024.

Murray Fingeret, OD, chief of the optometry at the Department of Veterans Administration New York Harbor Healthcare System in New York City, tested latanoprostene bunod and backed it as an effective remedy for glaucoma.

Additionally, Valeant’s auto-immune medication brodalumab was rejected by the FDA due to concerns regarding how the product is labelled rather than the efficacy of the product itself. Six of 6,000 patients who used the drug committed suicide, marking a 300% increase over the average of two suicides per 6,000.

Naturally, there could be other factors contributing to these statistics, and Valeant has three months to hash out the details of the product before receiving FDA approval. Experts have also backed the medication as an effective treatment for the skin condition, psoriasis.

Nevertheless, investors have good reason to be cautious in committing to the stock in the short term as third-quarter earnings were 18 cents per share below estimate, while revenue fell 11% year over year. Additionally, the company took a goodwill impairment charge of $1.05 billion.

On top of these figures, Valeant seems like it will be gloomy in 2017 as numerous company medications are losing exclusivity, including its heavy-metal toxicity treatment Syprine, heart drug Nitropress, hepatitis C medication Virazole, and blood-pressure treatment Isuprel. Irritable-bowel-syndrome medication Xifaxan was named as the company’s “billion-dollar product of 2016” by its former boss, and it has been a total fiasco.

Additionally, Valeant is $30 billion in debt and it needs a controller, a head of quality, and solid advice to give the company the necessary boost it needs.

Despite it all, CEO Joe Papa seems optimistic; the company expects to have its debt re-cued to $5 billion by 2018, while prices for skin products are rising by an average of 40%. Between the potential of brodalumab and latanoprostene bunod, Valeant may be making the first steps towards its turnaround efforts. However, the decline of its core products will continue to push down the stock through the rest of the year and much of 2017.

The company is currently in the process of selling some assets to help reduce its debt, including its Salix unit, which may be acquired by Japanese pharma Takeda for $10 billion ($5 billion lower than what Valeant shelled out for it in 2015).

Valeant shares are down 1.8% at Tuesday’s market close with the stock trading at $23.05. Valeant has a market cap of $8 billion.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Karl Utermohlen has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

woman looks out at horizon
Stocks for Beginners

3 Beginner-Friendly Stocks Perfect for Canadians Starting Out in November

Are you looking for some of the best beginner-friendly stocks to line your portfolio? Here's a trio of picks to…

Read more »

A meter measures energy use.
Dividend Stocks

Is Fortis Stock a Buy, Sell, or Hold for 2025?

Fortis has increased its dividend annually for the past five decades.

Read more »

analyze data
Dividend Stocks

3 Dividend Stocks That Are Screaming Buys in November

Here are three top dividend stocks long-term investors won't want to ignore during this part of the market cycle.

Read more »

analyze data
Energy Stocks

Buy 8,850 Shares of This Top Dividend Stock for $2,000/Month in Passive Income

Let's do the math on what it would take to generate $2,000 a month in passive income from Enbridge (TSX:ENB)…

Read more »

senior relaxes in hammock with e-book
Dividend Stocks

Generate $175/Month in Passive Income With a $30,000 Investment

Dividend aristocrats offer reliability, and many of them also offer generous yields. With sizable enough discounts, these yields can become…

Read more »

dividends can compound over time
Dividend Stocks

Best Dividend Stocks to Buy Now for Canadian Investors

These three stocks would be excellent additions to your portfolios, given their solid underlying businesses, consistent dividend growth, and healthy…

Read more »

hand stacking money coins
Investing

A Few Years From Now, You’ll Wish You’d Bought This Undervalued Stock

A modestly undervalued stock with decent growth momentum may not be compelling to some investors. However, its business model and…

Read more »

Confused person shrugging
Investing

Gold vs. Energy: Better Stocks for November?

Different demand-and-supply cycles, geo-political factors, and economic conditions influence gold and energy stocks.

Read more »